$IVDN Feature: $1 Million Milestone & Continued

New Post Public Reply Private Reply Replies (1) Message Board
Lee Adams Lee Adams #25421
100
$IVDN Feature: $1 Million Milestone & Continued Profitability Projected for First Half of 2025 with Accelerating Sales for Key Supplier in Multi-Billion Homebuilding Industry: Innovative Designs, Inc. (Symbol: IVDN)
By: Get News
April 07, 2025 at 16:46 PM EDT
https://markets.financialcontent.com/streetin...mbol-ivdn/

From the article:

$IVDN New Board Member for Superior Insulation Maker has Ties to Industry Leaders Including D.R. Horton $DHI, Ryan Homes $NVR and More / Super Small Share Structure with Only 38 Million OS / 16 Million Float
Sole Maker of Patented Insultex® Insulation Delivering Construction Cost and Energy Saving Performance Superior to All Competition.
Unique Evacuated Cell House Wrap Material Provides an Unmatched R-6 Rating, Water Vapor, Air & Wind Barrier and Other Important Advantages.
Over $1 Million in Revenue with Profitability Projected in the First Half of 2025.
Fiscal First Quarter Results Deliver Over a 720% Increase, Largest Percentage Revenue Growth in Company History.
Profitability Reached for First Time at Fiscal 2024 Year-End on Almost 300% Revenue Increase vs. Previous Year.
New Government Building Codes Require Continuous Insulation with Higher Performance. IVDN Meets or Exceeds These Standards Where Many Competitors Now Do Not.
Increased Order Fulfilment Capabilities with Plans for Further Enhancement to Handle Strongly Increasing Demand.
Process Underway for Uplisting to OTCQB Tier.
New Board Member is Experienced Real Estate Developer with Relations to Top Homebuilding Names Including D.R. Horton, NVR / Ryan Homes and More.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Understanding Rollins' Current Market Position and Outlook

Updated Category News Views 226

Analyzing Rollins Inc.'s Stock Performance As we look at the current performance of Rollins Inc. (NYSE: ROL), the shares are trading around $55.73, reflecting a decrease of 1.24% in the recent session. While the stock has dipped by 3.81% over the past month, it has impressively increased by 10.91% year-over-year. This presents a curious juxtaposition of short-term...

Continue Reading
Silver One Reports Major Mineral Resource Estimate for Candelaria

Updated Category News Views 199

Candelaria Project Mineral Resource Estimate Silver One Resources Inc. (OTCQX: SLVRF) has made a significant announcement regarding the completion of a mineral resource estimate for the Candelaria Project. This estimate is prepared in accordance with the National Instrument 43-101, ensuring that the resources are assessed with high standards of transparency and accuracy....

Continue Reading
Investors Alert: Zynex (ZYXI) Faces Serious Legal Scrutiny

Updated Category News Views 197

Legal Investigation into Zynex, Inc. The Law Offices of Frank R. Cruz have announced a crucial investigation regarding Zynex, Inc. (ZYXI) focused on potential violations of federal securities laws. This investigation comes as a response to significant concerns raised about the company's recent financial disclosures and their implications for investors. Understanding the...

Continue Reading
Understanding Rentokil Initial's Stock Valuation Insights

Updated Category News Views 100

Assessing Rentokil Initial's Stock Performance In the current trading session, Rentokil Initial Inc. (NYSE: RTO) shares are priced at $26.42, witnessing a notable increase of 1.46%. Over the past month, the stock has gained 1.40%, though it has faced a decline of 7.78% in the last year. This fluctuation raises questions among shareholders regarding its valuation, despite...

Continue Reading
Innovative Insights on Efzofitimod from aTyr Pharma's Recent Conference

Updated Category News Views 177

aTyr Pharma Highlights Efzofitimod at Key Conference At a significant scientific gathering, aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology firm known for its innovative therapeutic approaches, shared compelling data concerning efzofitimod. This presentation underlined important insights about the treatment of pulmonary sarcoidosis. The conference, which...

Continue Reading